On Monday, Shares of Darling Ingredients Inc (NYSE:DAR), lost -0.96% to $15.49.
Darling Ingredients Inc., declared financial results for the first quarter ended April 4, 2015.
For the first quarter of 2015, the Company reported net sales of $874.7 million, as compared with net sales of $946.3 million for the first quarter of 2014. The $71.6 million decrease in net sales is primarily attributable to lower finished product prices, primarily global fat markets, and the foreign exchange rate impact of a weaker euro and Canadian dollar. Raw material volumes globally were stronger year over year.
Darling Ingredients Inc. develops, produces, and sells natural ingredients from edible and inedible bio-nutrients worldwide. It operates in three segments: Feed Ingredients, Food Ingredients, and Fuel Ingredients.
Shares of Baxter International Inc.(NYSE:BAX), declined -1.60% to $68.25, during its last trading session.
In advance of the anticipated July 1, 2015, spin-off of Baxalta Incorporated from Baxter International Inc. (BAX), executives from the companies will share their vision, strategies and initiatives underway to drive product innovation and accelerated growth over the long-term. Each company will provide updates on its financial outlook, new product pipeline and growth prospects at a two-day conference that begins today.
As separate, independent companies, both Baxter and Baxalta will remain leaders in their respective markets, each with an established global presence. The businesses operate in distinct markets, and each possesses unique and compelling growth prospects, investment requirements and risk profiles. Both companies will have strong balance sheets and cash flows, and will benefit from enhanced financial flexibility and reduced complexity. This will allow each to prioritize and capitalize on unique opportunities presenting the highest growth potential within their respective portfolios.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products.
At the end of Monday’s trade, Shares of Medical Properties Trust, Inc. (NYSE:MPW), gained 0.36% to $13.86.
Medical Properties Trust, Inc., declared that its Board of Directors declared a regular quarterly cash dividend of $0.22 per share of common stock to be paid on July 9, 2015, to stockholders of record on June 11, 2015.
Medical Properties Trust, Inc. operates as a real estate investment trust (REIT) in the United States. It acquires, develops, and invests in healthcare facilities; and leases healthcare facilities to healthcare operating companies and healthcare providers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
